Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy.

Cancer. 1986 Apr 15;57(8 Suppl):1657-61. Unique Identifier : AIDSLINE MED/86133156
Mitsuyasu RT; Taylor JM; Glaspy J; Fahey JL

Abstract: Kaposi's sarcoma (KS) in acquired immune deficiency syndrome (AIDS) is a new manifestation of a previously rare disease, and generally has a fatal course. Variations in the clinical course and in response to treatment by patients with this disease suggest that specific immunologic or clinical parameters may be important in the prognosis. Retrospective analyses of clinical parameters with respect to survival in 96 patients with epidemic Kaposi's sarcoma indicated that earlier tumor stage, the lack of prior opportunistic infections, and the absence of systemic symptoms correlated most closely with survival. Sixteen immune parameters were also assessed for their prognostic value. Total T4 (CD-4) cell number levels and the T4: T8 ratio correlated most closely with survival. Response to treatment with recombinant alpha interferons, while not well correlated with tumor stage, was more frequent in patients without systemic symptoms or a history or prior opportunistic infections. Treatment response was associated with a greater degree of intact T-cell function. These findings emphasize the importance of cellular immunity in the pathogenesis and subsequent course of patients with epidemic Kaposi's sarcoma, suggesting that different therapeutic strategies may be necessary to address specific prognostic subgroups.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Antigen-Antibody Complex/ANALYSIS Antigens, Surface/ANALYSIS Human IgA/ANALYSIS Interferon Type I/THERAPEUTIC USE Leukocyte Count Lymphocyte Transformation Prognosis Recombinant Proteins/THERAPEUTIC USE Sarcoma, Kaposi's/ETIOLOGY/*IMMUNOLOGY/THERAPY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes/IMMUNOLOGY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDcomplicationsantigen-antibodycomplex/analysisantigens,surface/analysishumaniga/analysisinterferontypei/therapeuticuseleukocytecountlymphocytetransformationprognosisrecombinantproteins/therapeuticusesarcoma,kaposi's/etiology/KWDimmunology/therapysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDt-lymphocytes/immunologyjournalarticle
860630
M8660160

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .